No information is available on the clinical use of riociguat during breastfeeding. Because riociguat is 95% bound to plasma proteins, the amount in milk is likely to be low. The manufacturer recommends that breastfeeding be avoided during riociguat use. The drug should be absent from breastmilk 3 days after the last dose.
Drug Levels
Maternal Levels. Relevant published information was not found as of the revision date.
Infant Levels. Relevant published information was not found as of the revision date.
Effects in Breastfed Infants
Relevant published information was not found as of the revision date.
Effects on Lactation and Breastmilk
Relevant published information was not found as of the revision date.
Disclaimer: Information presented in this database is not meant as a substitute for professional judgment. You should consult your healthcare provider for breastfeeding advice related to your particular situation. The U.S. government does not warrant or assume any liability or responsibility for the accuracy or completeness of the information on this Site.
